PureRawz vs. Swiss Chems: Which Offers Better Purity and Value in 2025?
So which company truly delivers the best quality and service?
Let's dive into a detailed comparison and see why PureRawz consistently leads, while Swiss Chems struggles to keep up.
✅ Quick Comparison Table: PureRawz vs. Swiss Chems (2025) Feature PureRawz Swiss Chems Purity Testing ✅ 3rd-party lab-tested with certificates ⚠️ Claims testing, but limited public reports Transparency ✅ Lab results available on product pages ❌ Hard to find or outdated results Product Range ✅ SARMs, peptides, nootropics, PCT, blends ⚠️ SARMs-heavy, limited peptide options Innovation ✅ Frequently launches new compounds ❌ Rarely updates product lineup Shipping Speed ✅ Fast U.S. & international shipping ⚠️ Mixed reviews about delays Customer Support
✅ 24/7 support via chat and email ❌ Slow or unresponsive according to users Refund Policy ✅ Professional, secure, and labeled ⚠️ Inconsistent packaging reports Packaging Quality ✅ Professional, secure, and labeled ⚠️ Inconsistent packaging reports Pricing 💰 Competitive with loyalty points & bundles 💰 Occasionally cheaper, but less reliable Trustworthiness ⭐ Rated highly in online communities ⚠️ Trust issues due to purity concerns
The most important factor in 2025 when buying research compounds is purity. If a product isn't exactly what it claims to be, your research could be compromised—and worse, potentially dangerous.
PureRawz goes the extra mile with third-party lab testing on every batch. They don't just claim it—they publish the Certificates of Analysis (COAs) right on each product page. Researchers know exactly what they're getting, down to the molecular structure and purity percentage.
Swiss Chems says their products are tested, but very few lab reports are shared publicly. Even when available, they're often outdated. This lack of transparency makes it hard for researchers to feel fully confident in the products. 👉 Winner: PureRawz — Reliable lab reports and public trust.
With the evolving world of performance enhancement and cognitive research, companies need to offer more than just SARMs.
PureRawz offers: SARMs (Ostarine, RAD-140, MK-677, etc.)
Peptides (BPC-157, TB-500, Semaglutide, and more)
Nootropics (Phenibut, Tianeptine, Bromantane)
PCT and anti-estrogen solutions
Custom blends for advanced protocols
They also frequently introduce new research compounds based on market demand and scientific developments.
Swiss Chems tends to stick to older SARMs and a few peptides. They rarely launch new products, and their inventory feels stagnant.
👉 Winner: PureRawz — More variety, more innovation.
When dealing with sensitive compounds, fast and discreet shipping is key.
Orders from PureRawz usually ship within 24–48 hours. U.S. customers report 2–4 day delivery times, and international shipments arrive in about a week. Their discreet packaging, secure labeling, and responsive team create a professional and stress-free experience.
Swiss Chems has had mixed reviews about shipping times and tracking updates. Some users complain about poor packaging, unmarked bottles, or delayed shipments. Their support team also lacks the responsiveness seen with PureRawz.
👉 Winner: PureRawz — Fast shipping and great service.
Price is important—but not if it means sacrificing quality or safety.
PureRawz keeps prices competitive, but what makes them stand out is their: Loyalty points for repeat customers
Bundle deals and discounts
Verified purity, so you know you're not wasting money
Yes, Swiss Chems might undercut prices occasionally. But saving a few bucks means nothing if the compound isn't pure, doesn't arrive on time, or isn't what you ordered.
👉 Winner: PureRawz — Better value for every dollar spent.
Online forums and Reddit threads often reveal what real users think. PureRawz is consistently praised for professionalism, fast service, and reliable quality.
Swiss Chems has a mixed reputation, with users raising concerns about quality control and unresponsive customer service.
👉 Winner: PureRawz — Trusted by the community.
If you're serious about research in 2025, you need a source that offers high-purity compounds, clear lab data, and professional service. Based on every meaningful metric, PureRawz comes out on top. Key Metric Winner Purity & Testing ✅ PureRawz Product Innovation ✅ PureRawz Shipping & Service ✅ PureRawz Value for Money ✅ PureRawz Trust & Reputation ✅ PureRaw
TIME BUSINESS NEWS
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
21 hours ago
- Business Insider
I upgraded to premium economy for a 13-hour flight on a budget airline. It lacked some perks, but it was still worth the price.
Norse Atlantic Airways offers some of the cheapest flights to Europe from the US. The budget airline, which launched in 2022, offers direct routes to European destinations, including Athens, Paris, London, Berlin, Stockholm, and Rome. It also has flights to Bangkok, Phuket, and Cape Town. If you're in the US, you can fly the airline out of LA, New York City, Miami, and Orlando. Prices vary widely depending on the route and season, but economy tickets are available for as low as $189 to fly from LA to Athens in July or $116 to travel from New York to Rome. Norse Atlantic only flies Boeing 787 Dreamliners, and only offers economy and premium economy seats on its planes. Before my trip, I decided to upgrade to a premium economy seat. Norse Atlantic offers three types of economy tickets, as well as premium economy. I originally booked an economy classic ticket for the flight, which cost me $503 and included one personal item, one carry-on bag, one standard checked bag, one in-flight meal, and general boarding. A week later, I upgraded to premium economy for an additional $677. The trip cost me $1,180 total, which was still cheaper than the economy seats I saw offered by other carriers for non-direct flights. My journey began at the priority check-in line at Athens International Airport. Since I had a premium economy seat, I was allowed to use Norse Atlantic's priority line, which was empty when I arrived at the airport. I breezed right to the front, immediately checked in my bag, and got my boarding pass. As I walked to security, I counted at least 10 people waiting in the standard check-in line. My premium economy ticket also gave me priority boarding, although I accidentally missed my chance. I spent so much time debating which olive oil to buy at one of the duty-free shops that when I arrived at the gate, my flight was already boarding group three. There was a long line of people waiting to board, and a Norse employee was checking tickets before allowing us to enter the roped-off gate. When he saw my premium economy ticket, he said I had missed my chance and would have to wait with everyone else to get on the plane. I probably had to wait about 15 minutes in line to board, but the bag full of Greek olive oil, ouzo, and chocolate was worth it. A flight attendant directed me to premium economy's separate section at the front of the plane. I was pleasantly surprised when I found my window seat and realized just how much extra space I'd have in premium economy. The comfortable seats are 19.5 inches wide, compared to 17 inches in economy, and have wider armrests, which also act as storage compartments for the entertainment system and tray table. My seat had way more legroom than I expected. Norse Atlantic's premium economy seats offer 43 inches of seat pitch — the distance between each row of seats on a plane — compared to 31 inches in economy. It's among the most generous premium economy seat pitches across the major airlines, as seen by comparative numbers on SeatGuru. Since there was also ample overhead space, I didn't even have to store my backpack underneath the seat in front of me. My seat came with a pillow and a thick blanket, which were both wrapped in plastic. An attendant passed out water and juice as I unwrapped the soft blue blanket, which felt like fleece and kept me warm throughout the flight. While the blanket was free in premium economy, it would have cost me $7 in economy. Norse Atlantic also offers a $9 "comfort kit" with a neck pillow, earplugs, and a sleep mask for those in economy. Premium economy passengers also received complimentary earphones and earplugs. Shortly after takeoff, a flight attendant took my drink order. I sighed happily as I sipped my complimentary prosecco and stretched out my legs. As someone usually stuck next to the bathroom at the back of the plane, premium economy was feeling pretty great. Norse Atlantic serves two hot meals in premium economy. The first came about an hour after takeoff. We had a choice of chicken or pasta. I opted for the latter, which was a meat lasagna. The meal came with a bread roll, a small Greek salad, and halva for dessert. We were also provided with wooden utensils and cute mini salt and pepper shakers. The warm and cheesy lasagna was solid — definitely better than most of the pasta dishes I've tried during long-haul flights with US airlines. I also enjoyed the Greek salad and the provided dressing, although I found the halva a bit cloying. One of the biggest letdowns was Norse's in-flight entertainment offerings. I don't have an iPad and hate watching movies on my phone, so I typically depend on airlines' in-flight entertainment systems to keep me occupied on long flights. It's never really been an issue! On a recent Singapore Airlines flight, I had access to more than 1,900 on-demand options, including just about every recent Oscar nominee. But the Norse movie selection was… rough. I counted only 120 films total (in the name of good journalism) and found the offerings to be extremely random. Most seemed like straight-to-DVD movies from the 1990s, scraped from the bottom of the Rotten Tomatoes barrel. When I started getting sleepy, I took advantage of my seat's footrest. While it wasn't a lie-flat experience like you'd typically find in business or first class, I appreciated the premium economy perk of having a footrest that went up about halfway to my seat. I also used the seat-back ordering service whenever I got thirsty. I loved that I could easily order drinks from my in-flight entertainment system, which offered a menu of complimentary hot and cold beverages, including alcohol, throughout the flight. At one point during the flight, I ordered a ginger ale, which an attendant delivered to my seat about 20 minutes later. Drinks are only complimentary throughout the flight if you're in premium economy. Passengers in economy only receive one free drink during the flight. I browsed Norse Atlantic's menu and saw sodas for $4.30 and a water bottle for $3.70. A glass of wine will set you back at least $10.70 (or $15 if you want champagne). But snacks aren't free, no matter what seat you're in. When my stomach started to grumble around hour eight of the 13-hour flight, I realized we hadn't been served the mid-flight hot snack typically served on long-haul trips. We hadn't even been given a bag of pretzels or chips. As I browsed through the menu on my seat-back system, I realized none of the snacks were complimentary in premium economy. Pretzels and Pringles were priced around $4, while a small package of tortilla chips with nacho cheese was priced at $6. There was also a variety of candy options, including Haribo gummies and Kit Kats, ranging from $3 to $6. Hot snacks or meals were also available for purchase. I opted for a $6 instant soup. The menu also offered french fries, pasta fusilli, butter chicken with basmati rice, and instant noodle soup. An attendant delivered my soup cup, filled with hot water, about 20 minutes later. It was a solid and comforting snack to tide me over before the final meal of the flight. The second complimentary meal was delivered about an hour before we landed. The second in-flight meal was pretty sparse. The main dish was a warm meat pastry of some sort, served alongside a few cut-up pieces of fruit and the same halva dessert from our first meal. Overall, the complimentary meals on Norse Atlantic were decent, though far lighter than those I've had on other long-haul trips. Next time, I'd buy some fun snacks at the airport before my flight. I would definitely fly Norse Atlantic Airways again. For a 13-hour flight, I was far more comfortable in Norse Atlantic Airways' premium economy than I have been in economy with US airlines — and I got the added benefit of paying less and flying direct. Next time I fly Norse, whether it be economy or premium, I'll make sure to bring some extra snacks and borrow my boyfriend's iPad. But in tough economic times like these, I love that there's still an airline making it affordable to explore the world.
Business Wire
2 days ago
- Business Wire
U.S. FDA Accepts New Drug Application for Merck's Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection
BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for doravirine/islatravir (DOR/ISL), an investigational, once-daily, oral, two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The FDA has set a target action date of April 28, 2026, for the application under the Prescription Drug User Fee Act (PDUFA). 'Merck has been at the forefront of HIV research for more than 35 years and we are pleased to continue our work to innovate and deliver new options that aim to meet the needs of the HIV community,' said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. 'The health needs of people living with HIV often change over time – whether it's managing comorbidities or navigating complex medication regimens. We believe DOR/ISL, if approved, will represent an important new complete regimen option designed to help meet their diverse needs.' The NDA is based on findings at Week 48 of two pivotal Phase 3 clinical trials (MK-8591A-051 and MK-8591A-052) where DOR/ISL was demonstrated to be non-inferior to baseline antiretroviral therapy (bART) in the open-label trial MK-8591A-051 and non-inferior to bictegravir/emtrictabine/tenofovir alafenamide i [BIC/FTC/TAF (50mg/200mg/25mg)] in the double-blind trial MK-8591A-052. Across both trials, the safety profile of DOR/ISL was generally comparable to comparator baseline antiretroviral regimens in trial MK-8591A-051 and BIC/FTC/TAF in trial MK-8591A-052. Data from these trials were presented during the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco. About the Phase 3 Trial MK-8591A-051 MK-8591A-051 is a Phase 3, open-label, randomized, active-controlled clinical trial evaluating the efficacy and safety of a switch to investigational, oral, once-daily DOR/ISL (100mg/0.25mg) in adults with HIV-1 infection that has been virologically suppressed using ART. The primary efficacy endpoint was the percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48 (non-inferiority margin 4%). In this trial, 551 adults with HIV-1 RNA <50 copies/mL for three months or more on oral 2- or 3-drug ART, with no history of treatment failure and no known virologic resistance to DOR, were randomized 2:1 and switched to DOR/ISL (n=366) or continued bART (n=185), stratified by bART regimen. The median age of participants was 51 years; 39.7% were assigned female sex at birth, 45.4% were Black or African American, and 14.5% were Hispanic or Latine. At baseline, 64.2% were treated with an InSTI-based regimen, 30.3% with an NNRTI-based regimen, and 5.4% with a protease inhibitor (PI)-based regimen, with median duration on current ART of 3.8 years (IQR 2.0-6.3). About the Phase 3 Trial MK-8591A-052 MK-8591A-052 is a Phase 3, double-blind, randomized, active-controlled clinical trial to evaluate the efficacy and safety of a switch to investigational, oral, once-daily DOR/ISL (100mg/0.25mg) in adults with HIV-1 infection that has been virologically suppressed on BIC/FTC/TAF (50mg/200mg/25mg). The primary efficacy endpoint was the percentage of participants with HIV-1 RNA ≥50 copies/mL at Week 48 (non-inferiority margin 4%). In this trial, 513 adults with HIV-1 who had virologic suppression for three months or more on BIC/FTC/TAF, no history of treatment failure and no known resistance to DOR were randomized (2:1) and switched to DOR/ISL (n=342) or continued treatment with BIC/FTC/TAF (n=171). The median age of participants was 47 years; 21.4% were assigned female sex at birth, 30.8% were Black or African American, and 22.8% were Hispanic or Latine. The median duration of BIC/FTC/TAF treatment prior to trial enrollment was 3.4 years (IQR 2.0-5.0). About Islatravir (MK-8591) and Merck's HIV Research Islatravir (MK-8591), Merck's investigational nucleoside reverse transcriptase translocation inhibitor (NRTTI), blocks HIV-1 replication by multiple mechanisms including inhibition of reverse transcriptase translocation, resulting in immediate chain termination and induction of structural changes in the viral DNA, resulting in delayed chain termination. Islatravir is under evaluation in multiple ongoing early and late-stage clinical trials in combination with other antiretrovirals for potential daily and once-weekly treatments for HIV-1, with islatravir serving as the anchor medicine in the treatment regimens based on its potency and resistance profile. In addition to the MK-8591A-051 and MK-8591A-052 trials, ongoing Phase 3 trials of daily DOR/ISL (100mg /0.25mg) include MK-8591A-053 in people with HIV who had not previously received treatment (treatment-naïve), and MK-8591A-054 evaluating open-label DOR/ISL (100 mg/0.25 mg) in individuals who participated in earlier Phase 3 trials of DOR/ISL (100 mg/0.75 mg). Islatravir in combination with Gilead's lenacapavir is in Phase 3 development as a novel oral once-weekly treatment for HIV-1, and islatravir in combination with our company's investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) ulonivirine (MK-8507) is in Phase 2 development as an oral once-weekly treatment. Merck's commitment to researching NRTTIs includes MK-8527, an investigational, novel oral, once-monthly NRTTI candidate that is in Phase 2 development for HIV-1 pre-exposure prophylaxis (PrEP). For an overview of Merck's HIV treatment and prevention clinical development program, please click here. Merck's Commitment to HIV For more than 35 years, Merck has been committed to scientific research and discovery in HIV leading to scientific breakthroughs that have helped change HIV treatment. Our work has helped pioneer the development of new options across multiple drug classes to help those impacted by HIV. Today, we are developing a series of antiviral options designed to help people manage their HIV and to help prevent HIV, with the goal of reducing the growing burden of infection worldwide. We want to ensure people are not defined by HIV, and our work focuses on transformational innovations, collaborations with others in the global HIV community, and access initiatives aimed at helping to end the HIV epidemic for everyone. Indications and usage for PIFELTRO ® (doravirine) and DELSTRIGO ® (doravirine, lamivudine, and tenofovir disoproxil fumarate) in the U.S. PIFELTRO is indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in adult patients with no prior ARV treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to doravirine. DELSTRIGO is indicated as a complete regimen for the treatment of HIV-1 infection in adult patients with no prior ARV treatment history or to replace the current ARV regimen in those who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable ARV regimen with no history of treatment failure and no known substitutions associated with resistance to the individual components of DELSTRIGO. Selected Safety Information Warning: Posttreatment Acute Exacerbation of Hepatitis B Virus (HBV) for DELSTRIGO All patients with HIV-1 should be tested for the presence of HBV before initiating ARV therapy. Severe acute exacerbations of HBV have been reported in people with concomitant HIV-1 and HBV who have discontinued products containing lamivudine or tenofovir disoproxil fumarate (TDF), which are components of DELSTRIGO. Patients coinfected with HIV-1 and HBV who discontinue DELSTRIGO should be monitored with both clinical and laboratory follow-up for at least several months after stopping DELSTRIGO. If appropriate, initiation of anti-HBV therapy may be warranted. Contraindications PIFELTRO and DELSTRIGO are contraindicated when coadministered with drugs that are strong cytochrome P450 (CYP)3A enzyme inducers (including the anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, and phenytoin; the androgen receptor inhibitor enzalutamide; the antimycobacterials rifampin and rifapentine; the cytotoxic agent mitotane; and the herbal product St. John's wort (Hypericum perforatum)), as significant decreases in doravirine plasma concentrations may occur, which may decrease the effectiveness of DELSTRIGO and PIFELTRO. DELSTRIGO is contraindicated in patients with a previous hypersensitivity reaction to lamivudine. Warnings and Precautions Severe Skin Reactions Severe skin reactions, including Stevens-Johnson syndrome (SJS)/toxic epidermal necrolysis (TEN), have been reported during the postmarketing experience with doravirine-containing regimens. Discontinue PIFELTRO or DELSTRIGO, and other medications known to be associated with severe skin reactions, immediately if a painful rash with mucosal involvement or a progressive severe rash develops. Clinical status should be closely monitored, and appropriate therapy should be initiated. New or Worsening Renal Impairment Renal impairment, including cases of acute renal failure and Fanconi syndrome, have been reported with the use of TDF. DELSTRIGO should be avoided with concurrent or recent use of a nephrotoxic agent (eg, high-dose or multiple NSAIDs). Cases of acute renal failure after initiation of high-dose or multiple NSAIDs have been reported in people living with HIV with risk factors for renal dysfunction who appeared stable on TDF. Prior to or when initiating DELSTRIGO, and during treatment, assess serum creatinine, estimated creatinine clearance, urine glucose, and urine protein in all patients. In patients with chronic kidney disease, also assess serum phosphorus. Discontinue DELSTRIGO in patients who develop clinically significant decreases in renal function or evidence of Fanconi syndrome. Discontinue DELSTRIGO if estimated creatinine clearance declines below 50 mL/min. Bone Loss and Mineralization Defects In clinical trials in adults living with HIV, TDF was associated with slightly greater decreases in bone mineral density (BMD) and increases in biochemical markers of bone metabolism. Serum parathyroid hormone levels and 1,25 Vitamin D levels were also higher. Cases of osteomalacia associated with proximal renal tubulopathy have been reported with the use of TDF. The effects of TDF-associated changes in BMD and biochemical markers on long-term bone health and future fracture risk in adults are unknown. Immune Reconstitution Syndrome Immune reconstitution syndrome can occur, including the occurrence of autoimmune disorders with variable time to onset, which may necessitate further evaluation and treatment. Drug Interactions Because DELSTRIGO is a complete regimen, coadministration with other antiretroviral medications for the treatment of HIV-1 infection is not recommended. Coadministration of PIFELTRO with efavirenz, etravirine, or nevirapine is not recommended. If DELSTRIGO is coadministered with rifabutin, take one tablet of DELSTRIGO once daily, followed by one tablet of doravirine (PIFELTRO) approximately 12 hours after the dose of DELSTRIGO. If PIFELTRO is coadministered with rifabutin, increase PIFELTRO dosage to one tablet twice daily (approximately 12 hours apart). Consult the full Prescribing Information prior to and during treatment for more information on potential drug-drug interactions. Dosage and Administration/Specific Populations Renal Impairment Because DELSTRIGO is a fixed-dose combination tablet and the dosage of lamivudine and TDF cannot be adjusted, DELSTRIGO is not recommended in patients with estimated creatinine clearance less than 50 mL/min. Adverse Reactions The most common adverse reactions with DELSTRIGO (incidence ≥5%, all intensities) were dizziness (7%), nausea (5%), and abnormal dreams (5%). The most common adverse reactions with PIFELTRO (incidence ≥5%, all intensities) were nausea (7%), dizziness (7%), headache (6%), fatigue (6%), diarrhea (6%), abdominal pain (5%), and abnormal dreams (5%). By week 96 in DRIVE-FORWARD, 2% of adult participants in the PIFELTRO group and 3% in the darunavir+ritonavir (DRV+r) group had adverse events leading to discontinuation of study medication. By week 96 in DRIVE-AHEAD, 3% of adult participants in the DELSTRIGO group and 7% in the efavirenz (EFV)/emtricitabine (FTC)/TDF group had adverse events leading to discontinuation of study medication. In DRIVE-FORWARD, mean changes from baseline at week 48 in LDL-cholesterol (LDL-C) and non-HDL-cholesterol (non-HDL-C) were pre-specified. LDL-C: -4.6 mg/dL in the PIFELTRO group vs 9.5 mg/dL in the DRV+r group. Non-HDL-C: -5.4 mg/dL in the PIFELTRO group vs 13.7 mg/dL in the DRV+r group. The clinical benefits of these findings have not been demonstrated. In DRIVE-AHEAD, mean changes from baseline at week 48 in LDL-C and non-HDL-C were pre-specified. LDL-C: -2.1 mg/dL in the DELSTRIGO group vs 8.3 mg/dL in the EFV/FTC/TDF group. Non-HDL-C: -4.1 mg/dL in the DELSTRIGO group vs 12.7 mg/dL in the EFV/FTC/TDF group. The clinical benefits of these findings have not been demonstrated. In DRIVE-SHIFT, mean changes from baseline at week 24 in LDL-C and non-HDL-C were pre-specified. LDL-C: -16.3 mg/dL in the DELSTRIGO group vs -2.6 mg/dL in the PI + ritonavir group. Non-HDL-C: -24.8 mg/dL in the DELSTRIGO group vs -2.1 mg/dL in the PI + ritonavir group. The clinical benefits of these findings have not been demonstrated. In DRIVE-AHEAD, neuropsychiatric adverse events were reported in the three pre-specified categories of sleep disorders and disturbances, dizziness, and altered sensorium. Twelve percent of adult participants in the DELSTRIGO group and 26% in the EFV/FTC/TDF group reported neuropsychiatric adverse events of sleep disorders and disturbances; 9% in the DELSTRIGO group and 37% in the EFV/FTC/TDF group reported dizziness; and 4% in the DELSTRIGO group and 8% in the EFV/FTC/TDF group reported altered sensorium. The safety of DELSTRIGO in virologically-suppressed adults was based on week 48 data from participants in the DRIVE-SHIFT trial. Overall, the safety profile in virologically-suppressed adult participants was similar to that in participants with no ARV treatment history. Serum ALT and AST Elevations: In the DRIVE-SHIFT trial, 22% and 16% of participants in the immediate switch group experienced ALT and AST elevations greater than 1.25 X ULN, respectively, through 48 weeks on DELSTRIGO. For these ALT and AST elevations, no apparent patterns with regard to time to onset relative to switch were observed. One percent of participants had ALT or AST elevations greater than 5 X ULN through 48 weeks on DELSTRIGO. The ALT and AST elevations were generally asymptomatic, and not associated with bilirubin elevations. In comparison, 4% and 4% of participants in the delayed switch group experienced ALT and AST elevations of greater than 1.25 X ULN through 24 weeks on their baseline regimen. Pregnancy/Breastfeeding There is a pregnancy exposure registry that monitors pregnancy outcomes in individuals exposed to PIFELTRO or DELSTRIGO during pregnancy. Healthcare providers are encouraged to register patients by calling the Antiretroviral Pregnancy Registry (APR) at 1-800-258-4263. Inform individuals with HIV-1 infection of the potential risks of breastfeeding, including: (1) HIV-1 transmission (in HIV-1–negative infants), (2) developing viral resistance (in HIV-1–positive infants), and (3) serious adverse reactions in a breastfed infant similar to those seen in adults. About Merck At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn. Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA This news release of Merck & Co., Inc., Rahway, N.J., USA (the 'company') includes 'forward-looking statements' within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company's management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements. Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company's ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company's patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions. The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company's Annual Report on Form 10-K for the year ended December 31, 2024 and the company's other filings with the Securities and Exchange Commission (SEC) available at the SEC's Internet site (
Time Business News
3 days ago
- Time Business News
How Rad-140 Enhances Workout Intensity and Recovery
In the world of high-performance fitness and bodybuilding, recovery and training intensity are often what separate plateaus from progress. One compound that's consistently catching the attention of athletes looking for that extra edge is Rad-140, also known as Testolone. As a selective androgen receptor modulator (SARM), it offers muscle-enhancing benefits that are both powerful and specific. For those seeking lean muscle gains without the harsh side effects of traditional anabolic steroids, the increasing number of options like Rad 140 for sale has made it a go-to among lifters who value results and precision. But what really makes Rad-140 stand out is how it supports not just muscle development, but also your body's ability to recover from intense training. When combined with smart programming and nutrition, this compound can completely change how you train and how you bounce back. Rad-140 was originally developed to combat muscle wasting in patients with degenerative conditions. However, its potential in sports performance has become undeniable. The compound binds selectively to androgen receptors in muscle and bone tissue, activating anabolic signals without triggering the broader side effects typically associated with steroids. What does this mean in real-life results? Users often report a significant boost in strength within the first 1–2 weeks of using Rad-140. This translates to more reps, heavier lifts, and greater workload capacity. Whether you're focused on hypertrophy, powerlifting, or athletic conditioning, that extra push helps break through training barriers. One of Rad-140's most appreciated benefits is how it shortens the time needed between hard training sessions. Microtears in muscle fibers heal more efficiently, allowing you to train more frequently without overreaching. This becomes especially crucial during strength cycles or cutting phases where muscle preservation is vital. Rad-140 supports recovery through several physiological mechanisms. The first is its role in muscle protein synthesis, which becomes more efficient when androgen receptors are activated. Another aspect is hormonal balance. While Rad-140 can suppress natural testosterone production to a degree, it doesn't convert to estrogen. This means users don't typically experience the water retention, bloating, or emotional fluctuations that come with estrogenic side effects making recovery cleaner and more linear. Interestingly, compounds like the Itpp SARM are often discussed alongside Rad-140 for their role in oxygen utilization and muscular endurance. While Rad-140 is more anabolic, stacking strategies that include complementary compounds may amplify recovery even further. However, these should be handled with care and strategic planning. Most beginners start with 10 mg per day, while more experienced users may go up to 20 mg. It has a relatively long half-life, so once-daily dosing is sufficient. A typical cycle runs 8 to 12 weeks, followed by post-cycle therapy. Rad-140 performs best when paired with a solid resistance training plan and adequate protein intake. If you're running a deficit (cutting), this compound helps preserve muscle. If you're in a surplus (bulking), expect lean, dry gains without unnecessary fat or water weight. Although Rad-140 doesn't aromatize, it can suppress endogenous testosterone. A mild PCT lasting 4–6 weeks is usually sufficient to restore hormonal balance. Users often turn to natural testosterone boosters or selective estrogen receptor modulators (SERMs) to assist the recovery phase. Rad-140 doesn't promise overnight miracles, but its performance-enhancing potential is real. Based on user feedback and community experiences, here's what's typically seen during a standard cycle: 3–7 pounds of lean mass added in 8–10 weeks added in 8–10 weeks 10–20% increase in strength Improved vascularity and definition , especially during cutting , especially during cutting Faster recovery between training days, with less soreness A look at do SARMs expire and compound stability is worth noting here. Like other SARMs, Rad-140 should be stored correctly typically in a cool, dark place to maintain potency. If you're sourcing from less-regulated suppliers, always check for third-party testing to ensure quality and shelf-life. Despite its clean profile, Rad-140 isn't side-effect-free. The most common issues include: Test suppression – more noticeable at higher doses or longer cycles – more noticeable at higher doses or longer cycles Sleep disruption – some users report lighter sleep toward the end of a cycle – some users report lighter sleep toward the end of a cycle Mild aggression or irritability Hair shedding – rare but possible with higher androgenic activity These can usually be managed with responsible use, cycle breaks, and proper PCT. Compared to other compounds like Ostarine or LGD-4033, Rad-140 tends to provide stronger anabolic effects without the added weight or puffiness. It's particularly useful for bodybuilders, power athletes, and even cross-trainers who want strength without sacrificing lean conditioning. Its clean profile and effective recovery benefits make it ideal for: Deload weeks when athletes still want to maintain strength when athletes still want to maintain strength Cutting cycles where muscle preservation is a priority where muscle preservation is a priority Overreach training periods to reduce the risk of injury Across lifting forums, social media groups, and private circles, Rad-140's reputation continues to rise: 'I added almost 6 pounds of clean mass in 8 weeks and didn't feel flat once.' 'My deadlift jumped by 40 lbs by the end of the cycle. Zero bloat. Felt great.' 'Stacked with Cardarine for cardio. Recovery was next level.' These results reflect disciplined usage, proper dosing, and structured training—not just a reliance on the compound itself. Rad-140 continues to earn its spot among the most researched and respected SARMs in the fitness world. With its impressive balance of muscle-building and recovery-enhancing properties, it helps bridge the gap between hard training and optimal results. It's not a shortcut but a strategic addition to an already strong routine. If your training is consistent and your diet is dialed in, Rad-140 can help you push harder, recover smarter, and grow leaner without the baggage that comes with traditional anabolic agents. TIME BUSINESS NEWS
